Peddock Capital Advisors LLC lessened its position in shares of Johnson & Johnson (NYSE:JNJ) by 4.3% in the 3rd quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 8,482 shares of the company’s stock after selling 380 shares during the quarter. Peddock Capital Advisors LLC’s holdings in Johnson & Johnson were worth $1,103,000 at the end of the most recent quarter.
Several other large investors have also recently added to or reduced their stakes in the company. Harding Loevner LP purchased a new stake in Johnson & Johnson during the 2nd quarter worth about $106,000. Mitsubishi UFJ Securities Holdings Co. Ltd. increased its position in Johnson & Johnson by 29.9% during the 2nd quarter. Mitsubishi UFJ Securities Holdings Co. Ltd. now owns 870 shares of the company’s stock worth $115,000 after purchasing an additional 200 shares in the last quarter. IHT Wealth Management LLC increased its position in Johnson & Johnson by 46.4% during the 2nd quarter. IHT Wealth Management LLC now owns 10,942 shares of the company’s stock worth $122,000 after purchasing an additional 3,467 shares in the last quarter. Mountain Capital Investment Advisors Inc purchased a new stake in Johnson & Johnson during the 2nd quarter worth about $124,000. Finally, Shine Investment Advisory Services Inc. purchased a new stake in Johnson & Johnson during the 2nd quarter worth about $177,000. 67.35% of the stock is owned by institutional investors and hedge funds.
Shares of Johnson & Johnson (NYSE JNJ) opened at $132.63 on Tuesday. The company has a current ratio of 1.41, a quick ratio of 1.12 and a debt-to-equity ratio of 0.51. Johnson & Johnson has a fifty-two week low of $120.95 and a fifty-two week high of $148.32. The stock has a market capitalization of $358,972.31, a PE ratio of 18.33, a PEG ratio of 2.19 and a beta of 0.77.
The company also recently announced a quarterly dividend, which will be paid on Tuesday, March 13th. Stockholders of record on Tuesday, February 27th will be issued a dividend of $0.84 per share. This represents a $3.36 dividend on an annualized basis and a dividend yield of 2.53%. The ex-dividend date of this dividend is Monday, February 26th. Johnson & Johnson’s payout ratio is currently 861.54%.
In other news, VP Paulus Stoffels sold 155,342 shares of the business’s stock in a transaction dated Thursday, February 15th. The stock was sold at an average price of $129.86, for a total transaction of $20,172,712.12. Following the completion of the sale, the vice president now owns 357,906 shares in the company, valued at approximately $46,477,673.16. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. 0.19% of the stock is currently owned by insiders.
A number of analysts recently commented on the company. Citigroup dropped their price objective on Johnson & Johnson from $150.00 to $146.00 and set a “neutral” rating for the company in a research report on Tuesday, February 27th. Vetr upgraded Johnson & Johnson from a “hold” rating to a “buy” rating and set a $150.89 price objective for the company in a research report on Thursday, January 11th. Royal Bank of Canada reiterated a “buy” rating on shares of Johnson & Johnson in a research report on Tuesday, January 9th. Jefferies Group set a $165.00 price target on Johnson & Johnson and gave the company a “buy” rating in a report on Monday, February 26th. Finally, Stifel Nicolaus lifted their price target on Johnson & Johnson from $142.00 to $145.00 and gave the company a “hold” rating in a report on Wednesday, January 24th. Four equities research analysts have rated the stock with a sell rating, nine have assigned a hold rating, eight have given a buy rating and one has assigned a strong buy rating to the stock. The company has an average rating of “Hold” and a consensus price target of $146.26.
TRADEMARK VIOLATION NOTICE: This news story was originally posted by American Banking News and is owned by of American Banking News. If you are viewing this news story on another website, it was illegally copied and republished in violation of US & international trademark & copyright laws. The correct version of this news story can be accessed at https://www.americanbankingnews.com/2018/03/13/peddock-capital-advisors-llc-cuts-stake-in-johnson-johnson-jnj.html.
Johnson & Johnson Company Profile
Johnson & Johnson is a holding company, which is engaged in the research and development, manufacture and sale of a range of products in the healthcare field. It operates through three segments: Consumer, Pharmaceutical and Medical Devices. Its primary focus is products related to human health and well-being.
Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.